Surrozen, Inc. Common (SRZN) Stock: Buy, Sell, or Hold?
SRZN - Surrozen, Inc. Common
$25.75
0.43 (1.70%)
▲
5d:
+2.71%
30d:
+59.34%
90d:
+30.51%
HOLD
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 06, 2026
13d
Get Alerted When SRZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SRZN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SRZN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SRZN is currently trading at $25.75, which is considered fair relative to its 30-day fair value range of $19.21 to $29.86.
Technical Outlook: Technically, SRZN is showing sideways momentum. Immediate support is located at $21.85, while resistance sits at $30.97.
Market Sentiment: SRZN scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $48.40 (+88.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SRZN is showing sideways momentum. Immediate support is located at $21.85, while resistance sits at $30.97.
Market Sentiment: SRZN scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $48.40 (+88.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$19.21 -
$29.86
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
85.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (65/100)
- BULLISH: Trading 88.0% below Wall St target ($48.40)
- CAUTION: Bottoming setup, but lagging the sector by 11% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$19.21 -
$29.86
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$3.56
(13.8%)
Support & Resistance Levels
Support Level
$21.85
Resistance Level
$30.97
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.15
Wall Street Target
$48.40
(+88.0%)
Revenue Growth (YoY)
408.6%
Earnings Growth (YoY)
-37.0%
Share & Embed Analysis
Last updated: October 23, 2026 4:56 AM ET
Data refreshes hourly during market hours. Next update: 5:56 AM
Data refreshes hourly during market hours. Next update: 5:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 61 BUY |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |
